SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

PURPOSE OF REVIEW: This scoping review aims to identify and characterize analytic methods used to investigate digital communication related to HIV. RECENT FINDINGS: Of the 106 articles detailed in this...

Objective This systematic review and meta-analysis aims to characterize the distribution of HIV-1 viral tropism at diagnosis among people living with HIV (PLWH) and examine its association with baseline CD4+ T...

BACKGROUND: Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) offers potentials for expanding PrEP coverage and improving public health outcomes. This study synthesizes evidence on the prevalence and determinants of interest in and...

BACKGROUND: AIDS disease, caused by HIV, is a highly prevalent disease disturbing global health and swaying economic progress and social fidelity in the world. PURPOSE: Eradication and cure of HIV...

BACKGROUND: Viral suppression among children living with HIV remains suboptimal in sub-Saharan Africa. The marked heterogeneity in suppression rates across countries underscores the need for comparative analyses to elucidate context-specific...

Background The Joint United Nations Programme on HIV/AIDS (UNAIDS) has established the 95-95-95 targets, aiming that by 2030, 95% of individuals on ART will achieve viral suppression. While the number...

Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking....

The HIV epidemic in sub-Saharan Africa (SSA) continues to spread primarily through heterosexual contact, and in many countries, heterosexual men continue to exhibit a high HIV incidence with resultant morbidity...

Background: Dolutegravir (DTG) + lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe. Methods: To...

Background Antiretroviral (ARV) exposure influences the early-life gut microbiota in regions with high human immunodeficiency virus (HIV) burdens. Understanding how ARV drugs affect the infant gut microbiota is important for...

BACKGROUND: The COVID-19 pandemic caused significant disruptions to global healthcare systems, including essential services along the HIV care continuum (HCC). While several studies have examined these impacts in specific countries...

AIM: To systematically integrate the psychosocial experiences and coping mechanisms of AIDS patients after the disease, and to understand their true feelings, in order to provide a basis for better...